Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00532246 · ClinicalTrials.gov registry record · Phase 4
Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo
A Phase 4 study of Osteoporosis, Post-Menopausal, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 147
- Enrollment target
- 5
- Study locations
NCT00532246 is a Phase 4 study of Osteoporosis, Post-Menopausal that has completed, run by Eli Lilly and Company. The registered enrollment target is 147 participants. The trial reports 5 study locations across 1 state.
The verdict
NCT00532246, a Phase 4 study of Osteoporosis, Post-Menopausal, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 147 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to measure carotid artery IMT at a single visit in a subset of women previously enrolled in the CORE (H3S-MC-GGJY) trial
Conditions Studied
Interventions
- DRUG Placebo
- DRUG raloxifene
Study Locations (5)
California
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - La Jolla
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Menlo Park
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Oakland
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - San Diego
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Walnut Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2003-03 |
| Est. Completion | 2003-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00532246
The ClinicalTrials.gov registry entry for NCT00532246 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoporosis, Post-Menopausal appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00532246 reports 5 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00532246 about?
NCT00532246 is a clinical study titled "Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo". The purpose of this study is to measure carotid artery IMT at a single visit in a subset of women previously enrolled in the CORE (H3S-MC-GGJY) trial
What is the current status of trial NCT00532246?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 147 participants. The study started on 2003-03. Estimated completion is 2003-08.
What conditions does trial NCT00532246 study?
This clinical trial studies the following conditions: Osteoporosis, Post-Menopausal.
What interventions are being tested in trial NCT00532246?
The interventions under investigation include: Placebo (DRUG), raloxifene (DRUG).
Who is sponsoring clinical trial NCT00532246?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00532246 being conducted?
This trial has 5 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis, Post-Menopausal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.